Scarica l'app Stockscreener
96.74
0.54%
0.52
Dopo l'orario di chiusura:
96.74
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte (INCY) Stock Analysis | Incyte Corp Posts 8.5% EPS Miss Vs Consensus ViewsAcquisition - Cổng thông tin điện tử tỉnh Lào Cai
Incyte president, R&D head sells $1.8m in stock, acquires $1.2m in shares - Investing.com
INCYTE CORP (INCY) executive exercises options and sells 18,667 shares - Stock Titan
Incyte (INCY) to Present Phase 3 Tafasitamab Study Results at AS - GuruFocus
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 Americ - The National Law Review
Incyte to present tafasitamab lymphoma study results at ASCO - Investing.com
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire
Incyte discloses new TYK2 and/or JAK1 inhibitors - BioWorld News
Incyte to Report Q1 Results on April 28 - MyChesCo
Adagene and Incyte Partner to Develop Colorectal Cancer Therapy - HarianBasis.co
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer - Insider Monkey
Assessing Incyte (INCY) Valuation As Recent Returns Send Mixed Signals - Yahoo Finance
Here's Why Incyte (INCY) is a Strong Value Stock - Yahoo Finance
Incyte Corp. (NASDAQ:INCY) Presents a Compelling Value Investment Case - ChartMill
RBC Capital Lifts PT on Incyte Corporation (INCY) to $95 From $92 - Insider Monkey
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCYTE (NASDAQ: INCY) CEO granted 125,000 performance-based common shares - Stock Titan
INCYTE (INCY) R&D president earns 27,892 performance shares in equity award - Stock Titan
Incyte (NASDAQ: INCY) CMO earns 39,049 performance-based share award - Stock Titan
INCY (NASDAQ: INCY) Form 144 lists 18,667-share option exercise and prior sales - Stock Titan
INCY Forecast, Price Target & Analyst Ratings | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Shares Dip as Major Investor Reduces Stake - National Today
Incyte Corporation $INCY Holdings Lowered by Massachusetts Financial Services Co. MA - MarketBeat
Do Options Traders Know Something About Incyte Stock We Don't? - Yahoo Finance
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $135 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on hidradenitis drug - Investing.com
Incyte's (INCY) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
28,383 Shares in Incyte Corporation $INCY Purchased by Monument Capital Management - MarketBeat
Here's What to Expect From Incyte’s Next Earnings Report - Barchart.com
Robeco Institutional Asset Management B.V. Increases Stake in Incyte Corporation $INCY - MarketBeat
Beacon Harbor Wealth Advisors Boosts Incyte Corporation Holdings - National Today
INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup - ChartMill
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
Incyte Corp stock: What investors should know about its biotech potential now - AD HOC NEWS
Incyte to Report First Quarter 2026 Financial Results - National Today
L2 Asset Management, LLC's Incyte Corp(INCY) Holding History - GuruFocus
Incyte Corporation (INCY) stock price, news, quote and history - Yahoo Finance UK
Incyte to Report First Quarter Financial Results - ChartMill
Barclays Maintains Overweight on Incyte Corporation (INCY) March 24, 2026 - Meyka
Incyte Corp. stock rises Wednesday, still underperforms market - MarketWatch
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Drug Shows Reduced COPD-like HS Flares in Phase III Data - MyChesCo
Hidradenitis Suppurativa Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte Corp, CSL - Barchart.com
Incyte Names Cagnoni President, Announces Leadership Changes - MyChesCo
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte Corp. (INCY) reports Q4 2025 revenue growth of 28% to $1.51B driven by Jakafi and Opzelura sales - MSN
Allspring Global Investments Holdings LLC Buys 112,736 Shares of Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology CollaborationHas The Bull Case Changed? - Yahoo Finance
Toth Financial Advisory Corp Acquires Shares of 12,280 Incyte Corporation $INCY - MarketBeat
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp - Barchart
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key - openPR.com
2.53%
2.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):